Triazolam
FDA-approved product (tablet, oral), marketed as Halcion, Triazolam.
- Registered studies
- 17
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Benzodiazepine derivatives
- FDA pharmacologic class
- Benzodiazepine FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae13.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
17registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Triazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- RegadenosonExisting use: Cardiovascular disease, Myocardial Perfusion Imaging48.4% AI-predicted activityagainst E. coli50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma48.2% AI-predicted activityagainst E. coliNo documented evidence found
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- ClozapineExisting use: Psychosis, Schizoaffective disorder, Schizophrenia48.1% AI-predicted activityagainst E. coli50+ registered studies
- FutibatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm48.0% AI-predicted activityagainst E. coli25 registered studies
- Atazanavir SulfateExisting use: HIV infection, HIV-1 infection, Infection and 1 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Daclatasvir DihydrochlorideExisting use: Chronic hepatitis C virus infection, Viral disease48.0% AI-predicted activityagainst E. coli2 registered studies
- AripiprazoleExisting use: Aggressive behavior, Agitation, Autism and 8 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Alclometasone DipropionateExisting use: Eye inflammation, Skin disease47.9% AI-predicted activityagainst E. coli2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse
NCT00671632 · start 2003-06
Registered record
- Registry ID
- NCT00671632
- Conditions
- Drug Abuse
- Interventions
- Ramelteon, triazolam, and placebo (56 possible combinations total)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2003-12
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug AbuseInterventionRamelteon, triazolam, and placebo (56 possible combinations total)PhasePhase 2Registry statusCompletedEffectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine
NCT00218166 · start 2001-08
Registered record
- Registry ID
- NCT00218166
- Conditions
- Cocaine-Related Disorders
- Interventions
- GABA Agonists
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-08
- Completion
- 2005-05
- Enrolment
- 78
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionGABA AgonistsPhasePhase 2Registry statusCompleted